Jim Cramer’s Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026

17. Medline Inc. (NASDAQ:MDLN)

Number of Hedge Fund Holdings in Q3 2025: N/A

Number of Hedge Fund Holdings in Q1 2026: 65

Performance Since Cramer’s Remarks: 6.8%

Date/Month of Cramer’s Remarks: January 7th, 2026

Medline Inc. (NASDAQ:MDLN) is a large surgical instruments provider. Its shares are up by 5.3% over the past year and by 6.3% year-to-date. They are up by 6.8% since Cramer discussed the firm on Mad Money in January. One notable movement occurred on May 6th when the stock closed 7% lower. On that day, Medline Inc. (NASDAQ:MDLN) reported its fiscal first quarter earnings, which saw the firm post $7.4 billion in revenue and $0.33 in adjusted earnings per share. Additionally, the firm posted $239 million in net income to mark a 26% annual drop. The firm also suffered from a major fire in its distribution center in June. Here is what Cramer said about Medline Inc. (NASDAQ:MDLN) in January:

“But again, the fact that the IPO market was able to mostly self-correct in these situations and stamp out the froth, that’s what we really like, it’s a good thing for stocks in general. Just after Fermi came public, the IPO market went quiet for a while, thanks to the government shutdown that forced a much-needed cooling-off period for the IPO market, was good for us. After the government reopened, we ended up getting the largest deal in four years when Medline came public. Now, this is a medical supplies distributor and a medical device maker, highly thought of in the industry. Medline priced its IPO at $29, and the stock jumped to $41 on its first day of trading. Now, it’s just at 40 bucks and change. Now, this seems pretty healthy to me, and it’s a terrific company, and if the stock comes in, it’s a buy.”

Brown Advisory Mid-Cap Growth Strategy discussed Medline Inc. (NASDAQ:MDLN) in its fourth quarter 2025 investor letter:

“After following the company for years, we purchased shares of Medline Inc.’s (NASDAQ:MDLN) IPO in the quarter and subsequently added to our position. Medline is a differentiated business offering exposure to both medical technology demand and provider volumes through its vertically integrated manufacturing and distribution platform. The data from its scaled distribution business informs the higher margin manufacturing business, a key competitive advantage.”